Esckilsen, Scott
Kochar, Bharati
Weaver, Kimberly N.
Herfarth, Hans H.
Barnes, Edward L. http://orcid.org/0000-0001-9894-8796
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK127157-01)
Article History
Received: 16 November 2022
Accepted: 3 April 2023
First Online: 6 May 2023
Declarations
:
: Scott Esckilsen has no relevant disclosures. Bharati Kochar has served as a consultant for Pfizer. Kimberly N. Weaver has served as a consultant for AbbVie and BMS. Hans H. Herfarth has served as a consultant for Alivio, AMAG, Boehringer, BMS, ExeGi Pharma, Finch, Fresenius Kabi, Gilead, Janssen, Lycera, Merck, Otsuka, Pfizer, PureTech, Seres and research support from Allakos, Artizan Biosciences, Novo Nordisk and Pfizer. Edward L. Barnes has served as a consultant for AbbVie, Bristol-Meyers Squibb, Eli Lilly, and Target RWE.